Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation

被引:49
作者
Farina, Lucia [1 ]
Carniti, Cristiana
Dodero, Anna
Vendramin, Antonio
Raganato, Anna
Spina, Francesco
Patriarca, Francesca [2 ]
Narni, Franco [3 ]
Benedetti, Fabio [4 ]
Olivieri, Attilio [5 ]
Corradini, Paolo [6 ]
机构
[1] Univ Milan, Ist Nazl Studio & Cura Tumori, Div Hematol Bone Marrow Transplantat, Dept Hematol, I-20133 Milan, Italy
[2] Univ Udine, Dept Hematol, I-33100 Udine, Italy
[3] Univ Modena, Dept Hematol, I-41100 Modena, Italy
[4] Univ Verona, Dept Hematol, I-37100 Verona, Italy
[5] Azienda Osped San Carlo, Dept Hematol, Potenza, Italy
[6] Univ Milan, Chair Hematol, I-20122 Milan, Italy
来源
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷 / 05期
关键词
chronic lymphocytic leukemia; minimal residual disease; allogeneic stem cell transplantation; STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; VERSUS-HOST-DISEASE; HEMATOLOGIC MALIGNANCIES; MOLECULAR REMISSIONS; GENE; PCR; REARRANGEMENTS; GUIDELINES; SURVIVAL;
D O I
10.3324/haematol.2008.000273
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background The graft-versus-leukemia effect is able to induce clinical responses in patients with chronic lymphocytic leukemia treated with a reduced intensity conditioning regimen, followed by allogeneic stem cell transplantation. We investigated whether molecular remissions could be attained after reduced intensity conditioning and allogeneic stem cell transplantation in patients with relapsed chronic lymphocytic leukemia and whether the assessment of minimal residual disease might be used to predict the clinical outcome. Design and Methods Minimal residual disease was monitored by polymerase chain reaction using the immunoglobulin heavy-chain gene rearrangement as a molecular marker in 29 relapsed patients who achieved complete remission following reduced intensity conditioning and allogeneic stem cell transplantation. A nested-polymerase chain reaction with patient-specific primers derived from complementarity determining regions (CDR2 and CDR3) was carried out in all the patients. Real-time polymerase chain reaction was performed in patients whose nested reaction gave positive or mixed results. Results Three patterns of minimal residual disease were observed: negative (31%), mixed (24%), and always positive (45%). The cumulative incidence of relapse according to the minimal residual disease status at 6 and 12 months after transplantation was significantly different between polymerase chain reaction-negative and -positive patients (p=0.031 and p=0.04, respectively). Two-year disease-free survival was 93% and 46% for polymerase chain reaction-negative and -positive patients at 6 months after transplantation, respectively (p=0.012). Similarly, 2-year disease-free Survival was 100% and 57% for polymerase chain reaction-negative and -positive patients at 12 months, respectively (p=0.037). No clinical or biological factors were predictive of the achievement of polymerase chain reaction negativity after allogeneic stem cell transplantation. Graft-versus-host disease was more frequent in patients who did not relapse (p=0.04). Quantitative monitoring of minimal residual disease was able to identify polymerase chain reaction-positive patients with a higher risk of relapse. Conclusions These findings demonstrate that relapsed patients can achieve molecular remission after reduced intensity conditioning and allogeneic stem cell transplantation and suggest a minimal residual disease-driven intervention that might be useful to prevent overt hematologic relapse.
引用
收藏
页码:654 / 662
页数:9
相关论文
共 37 条
[1]
Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables [J].
Anderson, James R. ;
Cain, Kevin C. ;
Gelber, Richard D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) :3913-3915
[2]
ANALYSIS OF SURVIVAL BY TUMOR RESPONSE [J].
ANDERSON, JR ;
CAIN, KC ;
GELBER, RD .
JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (11) :710-719
[3]
Analysis of outcome by response flawed [J].
Anderson, JR ;
Neuberg, DS .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :8122-8123
[4]
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment [J].
Cheson, BD ;
Bennett, JM ;
Grever, M ;
Kay, N ;
Keating, MJ ;
OBrien, S ;
Rai, KR .
BLOOD, 1996, 87 (12) :4990-4997
[5]
Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome [J].
Corradini, P. ;
Dodero, A. ;
Farina, L. ;
Fanin, R. ;
Patriarca, F. ;
Miceli, R. ;
Matteucci, P. ;
Bregni, M. ;
Scime, R. ;
Narni, F. ;
Pogliani, E. ;
Locasciulli, A. ;
Milani, R. ;
Carniti, C. ;
Bacigalupo, A. ;
Rambaldi, A. ;
Bonifazi, F. ;
Olivieri, A. ;
Gianni, A. M. ;
Tarella, C. .
LEUKEMIA, 2007, 21 (11) :2316-2323
[6]
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies [J].
Corradini, P ;
Tarella, C ;
Olivieri, A ;
Gianni, AM ;
Voena, C ;
Zallio, F ;
Ladetto, M ;
Falda, M ;
Lucesole, M ;
Dodero, A ;
Ciceri, F ;
Benedetti, F ;
Rambaldi, A ;
Sajeva, MR ;
Tresoldi, M ;
Pileri, A ;
Bordignon, C ;
Bregni, M .
BLOOD, 2002, 99 (01) :75-82
[7]
CD8-depleted donor lymphocyte infusions can boost immune reconstitution after haploidentical stem cell transplantation following reduced-intensity conditioning regimen. [J].
Corradini, Paolo ;
Raganato, Anna ;
Carniti, Cristiana ;
Carrabba, Matteo ;
Lucia, Farina ;
Montefusco, Vittorio ;
Milani, Raffaella ;
Milanesi, Marco ;
Longoni, Paolo ;
Zorzan, Elisabetta ;
Gandola, Lorenza ;
Lombardo, Claudia ;
Dodero, Anna .
BLOOD, 2006, 108 (11) :895A-895A
[8]
Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study [J].
Delgado, J ;
Thomson, K ;
Russell, N ;
Ewing, J ;
Stewart, W ;
Cook, G ;
Devereux, S ;
Lovell, R ;
Chopra, R ;
Marks, DI ;
Mackinnon, S ;
Milligan, DW .
BLOOD, 2006, 107 (04) :1724-1730
[9]
Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia [J].
Doney, KC ;
Chauncey, T ;
Appelbaum, FR .
BONE MARROW TRANSPLANTATION, 2002, 29 (10) :817-823
[10]
The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia:: a risk-matched analysis based on the VH gene mutational status [J].
Dreger, P ;
Stilgenbauer, S ;
Benner, A ;
Ritgen, M ;
Kröber, A ;
Kneba, M ;
Schmitz, N ;
Döhner, H .
BLOOD, 2004, 103 (07) :2850-2858